Search
Displaying 181–190 of 689 for “retinitis clinical trial”
-
FFB Provides Four Career Development Awards to Up-and-Coming Clinical Researchers
Research NewsEach recipient will receive a total of $375,000 over five years to help build an independent research program in addition to their clinical practices.
-
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
-
Eye on the Cure Podcast | Episode 45: Henry Klassen, MD, PhD
Eye on the CureApril 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte’s clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
ARVO 2018: World's Largest Show and Tell for Innovations in Eye Research
Research NewsMore than 11,000 eye researchers from around the world — including five intrepid members from FFB’s science team — will gather to participate in what is essentially a massive “show and tell” of the latest scientific advancements.
-
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Research NewsKnown as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
ProQR Seeking to Partner Ophthalmic Programs
Research NewsThe company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner
-
AGTC Leverages Funding from the Foundation to Move Promising Treatments into Clinical Trials
Research NewsCompany Builds on FFB’s Initial Investment to Garner $265 Million in Therapy Development Funding
-
Fearless Sister Duo Finding Hope
Beacon StoriesApril LuFriu and Melissa Escobio are sisters and best friends who do just about everything together, including having retinitis pigmentosa (RP).
%20(7).png)
